Showing promise in the landscape of obesity treatment, retatrutide presents a different approach. Beyond many current medications, retatrutide operates as a double agonist, concurrently affecting both GLP-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) binding sites. The concurrent stimulation promotes several benefici